Jeanne Schilder

  • 2323 Citations
  • 21 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Jeanne Schilder is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Ovarian Neoplasms Medicine & Life Sciences
Platinum Medicine & Life Sciences
Topotecan Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Endometrial Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Publications 1997 2019

  • 2323 Citations
  • 21 h-Index
  • 45 Article
  • 4 Chapter
  • 1 Review article
2 Citations (Scopus)

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

TRINOVA-3/ENGOT-ov2/GOG-3001 investigators, Jun 1 2019, In : The Lancet Oncology. 20, 6, p. 862-876 15 p.

Research output: Contribution to journalArticle

Ovarian Neoplasms
Disease-Free Survival
10 Citations (Scopus)

Cell origins of high-grade serous ovarian cancer

Kim, J., Park, E. Y., Kim, O., Schilder, J., Coffey, D. M., Cho, C. H. & Bast, R. C., Nov 12 2018, In : Cancers. 10, 11, 433.

Research output: Contribution to journalReview article

Ovarian Neoplasms
Carcinoma in Situ
Fallopian Tubes
3 Citations (Scopus)

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

Tew, W. P., Sill, M. W., Walker, J. L., Secord, A. A., Bonebrake, A. J., Schilder, J., Stuckey, A., Rice, L., Tewari, K. S. & Aghajanian, C. A., Jan 1 2018, (Accepted/In press) In : Gynecologic Oncology.

Research output: Contribution to journalArticle

Fallopian Tubes
31 Citations (Scopus)

Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

Monk, B. J., Sill, M. W., Walker, J. L., Darus, C. J., Sutton, G., Tewari, K. S., Martin, L. P., Schilder, J., Coleman, R. L., Balkissoon, J. & Aghajanian, C., Jul 1 2016, In : Journal of Clinical Oncology. 34, 19, p. 2279-2286 8 p.

Research output: Contribution to journalArticle

Disease-Free Survival
Blood Vessels
Endothelial Growth Factors
26 Citations (Scopus)

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Bender, D., Sill, M. W., Lankes, H. A., Reyes, H. D., Darus, C. J., Delmore, J. E., Rotmensch, J., Gray, H. J., Mannel, R. S., Schilder, J., Hunter, M. I., McCourt, C. K., Samuelson, M. I. & Leslie, K. K., Sep 1 2015, In : Gynecologic Oncology. 138, 3, p. 507-512 6 p.

Research output: Contribution to journalArticle

Endometrial Neoplasms
Disease-Free Survival
Female Genital Diseases